Strong sales of diabetes and weight loss drugs Ozempic and Wegovy have prompted the Danish pharmaceutical company Novo Nordisk to raise its 2024 profit forecast to up to £15.3bn, with supply shortages starting to ease. Read More
Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn
Reading Time: < 1 minute